Neuromyelitis Optica Spectrum Disorder (NMOSD)
7
4
4
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia
Efficacy and Safety of Conventional Immunosuppressant Therapies in Elderly Patients With Neuromyelitis Optica Spectrum Disorder
Impact of a Structured Wellness Behavioral Intervention on Quality of Life in NMOSD
A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients